FASgen, Inc. Announces Research and License Agreement With Centocor, Inc.
...vel small molecule inhibitors of the fatty acid biosynthesis pathway via selective inhibition of Fatty Acid Synthase (FAS) for use in Oncology. The fasgen researchers have extensive experience studying the over-expression of FAS, an enzyme over-expressed in virtually all solid tumors. The inhibition of ...FASgen Diagnostic Tests Identify Ovarian Cancer Progression and Apoptosis
... BALTIMORE, March 26 /PRNewswire/ -- fasgen Diagnostics, LLC is pleased to report that results...pounds from FASgen, Inc., an affiliated company of fasgen Diagnostics, LLC, which makes FASi compounds inten...emoresistant and recurrent ovarian cancer. About fasgen Diagnostics, LLC and FASgen, Inc.: FASgen, Inc. is...FASgen Announces New Research Discoveries in Lung Cancer
... BALTIMORE, Dec. 28 /PRNewswire/ -- fasgen is pleased to report the publication of important research results for lung...nds. In a long-standing cooperation with The Johns Hopkins Oncology Center, fasgen supported research into the selective inhibition of fatty acid synthase (FA...FASgen Announces New Diagnostic Research Test for Steatohepatitis
... BALTIMORE, fasgen Inc. announced it has successfully expanded the po...dle biopsy. While only for research use presently, fasgen anticipates the opportunity for use of the non-inv.... FAS-Detect(TM) ELISA is a proprietary product of fasgen Diagnostics LLC, an affiliated...FASgen Announces a New Discovery in Obesity Research
... BALTIMORE, Dec. 21 /PRNewswire/ -- fasgen is pleased to report the publication of important ...AS89B, one of the Company's proprietary compounds. fasgen is a leader in the field of research into selectiv...8, 2007). This new discovery adds another tool for fasgen to use, in addition to FASi and GPATi compounds al...FASgen Announces New Discovery for Treatment of Stroke
... BALTIMORE, Dec. 20 /PRNewswire/ -- fasgen is pleased to announce the recent publication of important results from research into a potential treatment for stroke using one of FASgen's proprieta...FASgen Announces Significant Milestone in Its Cancer Drug Development Program
...n of FAS kills the cancer cell, a result that has been recently replicated in a number of labs and become the subject of a series of new publications. fasgen has developed a library of FASi compounds and has an extensive body of intellectual property surrounding both the mechanism of action and uses for the...FASgen Diagnostics, LLC Announces Production and Investment Agreement With Tetracore, Inc.
... BALTIMORE, May 29 /PRNewswire/ -- fasgen Diagnostics, LLC (Baltimore) and Tetracore, Inc. (...ing of the Society of Gynecological Oncologists. fasgen Diagnostics and Tetracore have been working togeth...e has also been given the opportunity to invest in fasgen Diagnostics. "We welcome the opportunity to expand...